SB590885Potent B-Raf inhibitor CAS# 405554-55-4 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 405554-55-4 | SDF | Download SDF |
PubChem ID | 11316960 | Appearance | Powder |
Formula | C27H27N5O2 | M.Wt | 453.55 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 33.33 mg/mL (73.49 mM; Need ultrasonic) | ||
Chemical Name | N,N-dimethyl-2-[4-[(4Z)-4-(1-nitroso-2,3-dihydroinden-5-ylidene)-5-(1H-pyridin-4-ylidene)-1H-imidazol-2-yl]phenoxy]ethanamine | ||
SMILES | CN(C)CCOC1=CC=C(C=C1)C2=NC(=C3C=CC4=C(CCC4=C3)N=O)C(=C5C=CNC=C5)N2 | ||
Standard InChIKey | DPCXEUSDRQOOGZ-QLYXXIJNSA-N | ||
Standard InChI | InChI=1S/C27H27N5O2/c1-32(2)15-16-34-22-7-3-19(4-8-22)27-29-25(18-11-13-28-14-12-18)26(30-27)21-5-9-23-20(17-21)6-10-24(23)31-33/h3-5,7-9,11-14,17,28H,6,10,15-16H2,1-2H3,(H,29,30)/b26-21- | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent B-Raf inhibitor (Kd = 0.3 nM). Selective for B-Raf against 46 other kinases (Ki app values are 0.16 and 1.72 nM for B-Raf and c-Raf respectively). Decreases anchorage-independent growth of melanoma cell lines. Inhibits ERK phosphorylation and proliferation in tumor cells expressing B-RafV600E. |
SB590885 Dilution Calculator
SB590885 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.2048 mL | 11.0241 mL | 22.0483 mL | 44.0966 mL | 55.1207 mL |
5 mM | 0.441 mL | 2.2048 mL | 4.4097 mL | 8.8193 mL | 11.0241 mL |
10 mM | 0.2205 mL | 1.1024 mL | 2.2048 mL | 4.4097 mL | 5.5121 mL |
50 mM | 0.0441 mL | 0.2205 mL | 0.441 mL | 0.8819 mL | 1.1024 mL |
100 mM | 0.022 mL | 0.1102 mL | 0.2205 mL | 0.441 mL | 0.5512 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
SB590885 is a potent and selective inhibitor of B-Raf kinase with Ki value of 0.16nM [1].
SB590885 is a potent inhibitor of oncogenic B-Raf protein kinase with Ki value of 0.16nM. It is more potent to inhibit B-Raf than C-Raf. The Ki value of SB590885 for C-Raf is 1.72nM. SB590885 is a quite selective inhibitor. It shows no activity against 48 other human kinases such as Abl, AMPK, CK1, CK2 and ERK2. It is found that SB590885 binds to B-Raf within the ATP-binding pocket and stabilizes the active conformation of B-Raf. SB590885 decreases the phosphorylation of ERK and shows anti-proliferation only in tumor cells expressing oncogenic B-Raf V600E. The normal cells and tumor cells not expressing mutant B-Raf have no sensitivity towards SB590885 except the normal melanocytes and primary melanoma cells expressing wild-type B-Raf. Moreover, SB590885 is also found to decrease the transformed and tumorigenic properties of malignant cells expressing mutant B-Raf [1].
References:
[1] King A J, Patrick D R, Batorsky R S, et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer research, 2006, 66(23): 11100-11105.
- Cyclapolin 9
Catalog No.:BCC7571
CAS No.:40533-25-3
- Dadahol A
Catalog No.:BCN5457
CAS No.:405281-76-7
- NFPS
Catalog No.:BCC7484
CAS No.:405225-21-0
- Dovitinib (TKI-258, CHIR-258)
Catalog No.:BCC1169
CAS No.:405169-16-6
- CHIR-124
Catalog No.:BCC3750
CAS No.:405168-58-3
- Besifloxacin HCl
Catalog No.:BCC4764
CAS No.:405165-61-9
- Drechslerine D
Catalog No.:BCN7502
CAS No.:405157-88-2
- Drechslerine A
Catalog No.:BCN7561
CAS No.:405157-84-8
- Salubrinal
Catalog No.:BCC4843
CAS No.:405060-95-9
- 4'-Demethylpodophyllotoxin
Catalog No.:BCN2625
CAS No.:40505-27-9
- Z-Lys(Z)-OH
Catalog No.:BCC2762
CAS No.:405-39-0
- LAQ824 (NVP-LAQ824,Dacinostat)
Catalog No.:BCC2160
CAS No.:404951-53-7
- GW3965
Catalog No.:BCC1612
CAS No.:405911-09-3
- GW3965 HCl
Catalog No.:BCC3790
CAS No.:405911-17-3
- C34
Catalog No.:BCC5603
CAS No.:40592-88-9
- Cirazoline hydrochloride
Catalog No.:BCC6833
CAS No.:40600-13-3
- DMT-Cl
Catalog No.:BCC2799
CAS No.:40615-36-9
- DMT-T
Catalog No.:BCC2843
CAS No.:40615-39-2
- DSP-4
Catalog No.:BCC7527
CAS No.:40616-75-9
- ACHP
Catalog No.:BCC6223
CAS No.:406208-42-2
- IKK-2 inhibitor VIII
Catalog No.:BCC1642
CAS No.:406209-26-5
- Cornoside
Catalog No.:BCN7575
CAS No.:40661-45-8
- Taxifolin 3-O-beta-D-xylopyranoside
Catalog No.:BCN5458
CAS No.:40672-47-7
- O-Phospho-L-serine
Catalog No.:BCC6578
CAS No.:407-41-0
Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells.[Pubmed:26081844]
J Cell Mol Med. 2015 Sep;19(9):2244-52.
Medullary thyroid cancer (MTC) is an aggressive malignancy responsible for up to 14% of all thyroid cancer-related deaths. It is characterized by point mutations in the rearranged during transfection (RET) proto-oncogene. The activated RET kinase is known to signal via extracellular signal regulated kinase (ERK) and phosphoinositide 3-kinase (PI3K), leading to enhanced proliferation and resistance to apoptosis. In the present work, we have investigated the effect of two serine/threonine-protein kinase B-Raf (BRAF) inhibitors (RAF265 and SB590885), and a PI3K inhibitor (ZSTK474), on RET-mediated signalling and proliferation in a MTC cell line (TT cells) harbouring the RETC634W activating mutation. The effects of the inhibitors on VEGFR2, PI3K/Akt and mitogen-activated protein kinases signalling pathways, cell cycle, apoptosis and calcitonin production were also investigated. Only the RAF265+ ZSTK474 combination synergistically reduced the viability of treated cells. We observed a strong decrease in phosphorylated VEGFR2 for RAF265+ ZSTK474 and a signal reduction in activated Akt for ZSTK474. The activated ERK signal also decreased after RAF265 and RAF265+ ZSTK474 treatments. Alone and in combination with ZSTK474, RAF265 induced a sustained increase in necrosis. Only RAF265, alone and combined with ZSTK474, prompted a significant drop in calcitonin production. Combination therapy using RAF265 and ZSTK47 proved effective in MTC, demonstrating a cytotoxic effect. As the two inhibitors have been successfully tested individually in clinical trials on other human cancers, our preclinical data support the feasibility of their combined use in aggressive MTC.
The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways.[Pubmed:24821574]
Invest New Drugs. 2014 Aug;32(4):626-35.
Papillary thyroid cancer (PTC) is the most frequent thyroid cancer entity, accounting for 88 % of cases. It may metastasize and loose iodine uptake capability, preventing any radioiodine or surgical treatment. The main gene altered in PTC is BRAF, which is found altered in over 50 % of cases. Moreover MAPK and PI3K/Akt pathways are greatly implicated in PTC development. Many target therapies for PTC are currently under investigation, unfortunately without the expected results. Aim of this study was to characterized the preclinical effectiveness of novel promising drugs, RAF265, SB590885 and ZSTK474 in 3 thyroid cancer cell lines (BCPAP, K1, 8505C). RAF265 and SB590885 target differentially BRAF, while ZSTK474 acts on PI3K. IC50 demonstrated high drug activities ranging from 0.1 to 6.2 muM, depending on drugs and cell type, while combination index revealed an interesting synergistic effect of combination regimen (RAF265 + ZSTK474 and SB590885 + ZSTK474) in almost all cell lines. Moreover this synergistic effect was particularly evident by Western blot, whereas dual MAPK and PI3K/Akt inhibition was detected. In addition, treating cells with SB590885 induced marked morphological changes, leading to massive vacuolization. This suggests an activation of apoptotic process, as underlined by Annexin V flow cytometry analysis. Also cell cycle was altered in treated cells, without evidence of a common pattern, but rather with a more specific effect relying on single drug or combination regimen used. Since beneficial effects of in vitro combination regimen (RAF265 + ZSTK474 and SB590885 + ZSTK474), it is recommended additional investigation. These data suggest the potential use of combination regimen in in vivo experiment or afterwards in human PTC.
B-RAF and its novel negative regulator reticulocalbin 1 (RCN1) modulates cardiomyocyte hypertrophy.[Pubmed:24492844]
Cardiovasc Res. 2014 Apr 1;102(1):88-96.
AIM: Activation of the kinase RAF and its downstream targets leads to cardiomyocyte hypertrophy. It has been hypothesized that B-RAF might be the main activator of MEK in various cell types. Therefore, the aim of this study was to investigate the role of B-RAF and its modulating factors in cardiomyocyte hypertrophy. METHODS AND RESULTS: Neonatal rat cardiomyocytes were pre-treated with and without the specific B-RAF inhibitor SB590885 and then stimulated with phenylephrine to induce hypertrophy. Inhibition of B-RAF completely impeded the hypertrophic response and led to a significant reduction of MEK1/2 phosphorylation. By applying a eukaryotic cDNA expression screen, based on a dual-luciferase reporter assay for B-RAF activity measurement, we identified RCN1 as a new negative modulator of B-RAF activity. Adenovirus-mediated overexpression of reticulocalbin 1 (RCN1) completely impeded phenylephrine-induced hypertrophy and led to significantly reduced MEK1/2 phosphorylation. Conversely, adenoviral knockdown of RCN1 with a specific synthetic miRNA induced cardiomyocyte hypertrophy and significantly increased MEK1/2 phosphorylation. CONCLUSIONS: In summary, our results show that the inhibition of B-RAF abolishes cardiomyocyte hypertrophy and we identified RCN1 as novel negative modulator of cardiomyocyte hypertrophy by inhibition of the mitogen-activated protein kinase signalling cascade. Our results show that B-RAF kinase activity is essential for cardiac hypertrophy and RCN1, its newly identified negative regulator, abolishes hypertrophic response of cardiomyocytes in vitro.
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.[Pubmed:17145850]
Cancer Res. 2006 Dec 1;66(23):11100-5.
Oncogenic BRAF alleles are both necessary and sufficient for cellular transformation, suggesting that chemical inhibition of the activated mutant protein kinase may reverse the tumor phenotype. Here, we report the characterization of SB-590885, a novel triarylimidazole that selectively inhibits Raf kinases with more potency towards B-Raf than c-Raf. Crystallographic analysis revealed that SB-590885 stabilizes the oncogenic B-Raf kinase domain in an active configuration, which is distinct from the previously reported mechanism of action of the multi-kinase inhibitor, BAY43-9006. Malignant cells expressing oncogenic B-Raf show selective inhibition of mitogen-activated protein kinase activation, proliferation, transformation, and tumorigenicity when exposed to SB-590885, whereas other cancer cell lines and normal cells display variable sensitivities or resistance to similar treatment. These studies support the validation of oncogenic B-Raf as a target for cancer therapy and provide the first evidence of a correlation between the expression of oncogenic BRAF alleles and a positive response to a selective B-Raf inhibitor.
The identification of potent and selective imidazole-based inhibitors of B-Raf kinase.[Pubmed:16260133]
Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81.
A novel triarylimidazole derivative, SB-590885 (33), bearing a 2,3-dihydro-1H-inden-1-one oxime substituent has been identified as a potent and extremely selective inhibitor of B-Raf kinase.